Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes

NICE recommends prolonged-release exenatide injections, in combination with other drugs (given as tablets), as a possible treatment for some people with type 2 diabetes (see below).

Who can have prolonged-release exenatide injections?

You should be able to have prolonged-release exenatide given with two other drugs (that is, with a drug called metformin and either a type of drug known as a sulphonylurea or a thiazolidinedione) if your blood glucose levels are not under control, and:

• you have a body mass index (BMI) of 35 or above and have health problems associated with this, or
• you have a BMI of less than 35, and treatment with insulin would make it much more difficult for you to do your job or other significant health problems would be helped by weight loss.

You should be able to have prolonged-release exenatide when given with one other drug (either metformin or a sulphonylurea) only if:

• you are not able to take either metformin or a sulphonylurea, and
• you are not able to take thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors.

You should be able to keep having injections of prolonged-release exenatide after 6 months only if tests show it is working well enough.

• Other information

  • TA248 Diabetes (type 2) - exenatide (prolonged release): guidance (web format)

  NICE Pathways

  This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.

  Visit the NICE Pathway: diabetes

  How this guidance was produced

  Background information

  • None found

Guidance formats

• Web format
• Full Guidance (PDF)
• Patient version (MS Word)

Diabetes (type 2) - exenatide (prolonged release)

Guideline for patients and carers (PDF)